Variant · Fusion
MLLT10 Fusion
CI-VAR-00001468Explore in graph →CIViC 5170
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37743097
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia1 | ||||||||
| PICALM::MLLT10 Fusion | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID12404In a retrospective cohort study of 39 pediatric AML patients carrying PICALM::MLLT10 fusions, both the 5-year event-free survival rate (22%) and 5-year overall survival rate (26%) were poor. PMID 37743097 · Mark et al., 2024 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.